Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
|ClinicalTrials.gov Identifier: NCT00493467|
Recruitment Status : Completed
First Posted : June 28, 2007
Last Update Posted : November 18, 2015
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Drug: Ibritumomab Tiuxetan (Zevalin) Drug: Rituximab||Phase 2|
90 Y Zevalin and rituximab are both designed to attach to lymphoma cells, causing them to die.
Before you can start treatment on this study, you will have "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. You will have a physical exam. Blood (about 2 to 3 teaspoons) and urine will be collected for routine tests. You will have a chest x-ray and computerized tomography (CT) scans of the neck, chest, abdomen (stomach area), and pelvis.
A PET scan is also recommended. A PET (Positron Emission Tomography) scan is a medical technique that monitors the activity in the brain and other organs by tracking the movement of a special radioactive solution through the body. The radioactive solution is either inhaled as a mist or injected into a vein. The radioactive solution is usually made from simple sugar that has radioactive particles attached to it. After the solution is injected into a vein or inhaled, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects in various organs. By watching how the solution travels through the body and studying where the solution collects, researchers can learn the extent of disease in certain organs in the body.
You will have an electrocardiogram (ECG -- a test that measures the electrical activity of the heart). You will have a bone marrow aspirate and biopsy performed. To collect a bone marrow aspirate and biopsy, an area of the hip or chest bone is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn through a large needle. Women who are able to have children must have a negative blood or urine pregnancy test.
If you are found to be eligible to take part in this study, you will be given diphenhydramine (Benadryl) by vein and you will take acetaminophen (Tylenol) by mouth before each dose of rituximab. This is done to help decrease the risk of developing side effects of rituximab. You will then receive 1 dose of rituximab by vein over about 4-6 hours on Day 1 of treatment. After treatment with rituximab, you will then be given 111 In Zevalin (this is a radioactive agent that binds to rituximab to help with imaging exams), by vein over about 10 minutes. This is so researchers can use a special camera to see where the drug is in your body.
You will have imaging performed (on a camera, like an x-ray) on either Day 2 or 3. On Day 8 (7 days after the first dose of rituximab) you will receive a second dose of rituximab. You will also be given Benadryl, Tylenol, and 90Y Zevalin in the same manner as on Day 1.
If you experience intolerable side effects while on this study, you may be removed from this study. Your treatment on the study will end on Day 8.
You will return for follow-up tests for 4 years. Blood (about 2 tablespoons) will be drawn weekly for the first 3 months. Blood (about 2 tablespoons each time) will also be drawn at month 6 and 9 of the first year, and every 6 months in the second, third, and fourth years. You may also have CT scans, PET scans (which are recommended), x-rays, and bone marrow biopsies and aspirates performed, if your doctor thinks they are necessary.
Your participation on this study will end in about 4 years.
This is an investigational study. 90 Y Zevalin and rituximab are FDA approved and commercially available. Their use in this study is investigational. Up to 36 patients will take part in this multicenter study. Up to 36 patients will be enrolled at M. D. Anderson.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas|
|Study Start Date :||June 2006|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||April 2015|
Ibritumomab Tiuxetan (Zevalin) + Rituximab
Drug: Ibritumomab Tiuxetan (Zevalin)
111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.
90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.
Other Names:Drug: Rituximab
250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
Other Name: Rituxan
- Overall Response Rate (ORR) [ Time Frame: Evaluation following completion of 12 weeks of treatment and performed by CT scan or MRI. ]ORR defined as the percentage of number of complete response or partial response in total number of patients treated using International Working Group (IWG) revised response criteria for Malignant Lymphoma. The treatment period is defined as 12 weeks from the 90Y Zevalin infusion. Overall response to therapy is evaluated after three months using radiographic and clinical parameters to assess response.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00493467
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Felipe Samaniego, MD||M.D. Anderson Cancer Center|